Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 5/20 | 0.51 |
| ▸ | ELOC | Q15369 | 2/20 | 0.44 |
| ▸ | ELOB | Q15370 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 7/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23880997 | 0.81 | VHL (0.60) | VHLELOCELOBKDM4EPKM | |
| SCHEMBL28610139 | 0.80 | VHL (0.55) | VHLKDM4EPKM | |
| SCHEMBL23037321 | 0.79 | ALDH1A1 (0.45) | VHLELOCELOBKDM4E | |
| Hydrochloric Acid SCHEMBL28668471 | 0.78 | VHL (0.54) | VHLKDM4EPKM | |
| SCHEMBL24880893 | 0.74 | VHL (0.52) | VHLELOCELOBKDM4EPKM | |
| SCHEMBL19600685 | 0.73 | VHL (0.54) | VHLELOCELOBKDM4EPKM | |
| SCHEMBL19661678 | 0.73 | VHL (0.53) | VHLELOCELOBKDM4EPKM | |
| SCHEMBL27394582 | 0.72 | VHL (0.48) | VHLKDM4EMLYCDPKM | |
| SCHEMBL23037368 | 0.72 | VHL (0.54) | VHLELOCELOB | |
| SCHEMBL19056956 | 0.72 | CES1 (0.65) | CES1MLYCDHDAC6MAP2K4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371426-B2 | Pyridazine derivatives as SMARCA2/4 degraders | AURIGENE DISCOVERY TECH LTD (IN) | 2025-07-29 | — | — | US | disclosed |
| US-20240270734-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | Aurigene Oncology Technologies Limited (IN) | 2024-08-15 | — | — | US | disclosed |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-08-19 | — | — | US | disclosed |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-08-19 | — | — | US | disclosed |
| CN-112771038-A | Pyridazine derivatives as SMARCA2/4 degradants | 奥里吉恩发现科技有限公司 | 2021-05-07 | — | — | CN | disclosed |
| EP-3784665-A1 | PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS | Aurigene Discovery Technologies Limited (IN) | 2021-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270734-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | SMARCC1, SMARCC2, SMARCA2 | VHL 271/4885ELOC 3332/4885ELOB 2891/4885 |
| US-12371426-B2 | Pyridazine derivatives as SMARCA2/4 degraders | SMARCC1, SMARCC2, SMARCA2 | VHL 259/4885ELOC 3327/4885ELOB 2848/4885 |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | SMARCC1, SMARCC2, SMARCA2 | VHL 271/4885ELOC 3332/4885ELOB 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.